ClinicalTrials.gg
CompletedNCT04753723Updated Oct 14, 2022

The Use of a Platform Wound Device for Reducing Infection

A Phase 4 interventional study of Gentamycin with Platform Wound Device in Wounds and Injury, Burn Wound and Infection Wound, sponsored by The Metis Foundation. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-10-14.

Primary conditionBurnsRegistry: Wounds and InjuriesReclassifiedWhy we changed it
Registry
Wounds and Injuries — the first condition term the registry derived for this study.
ClinicalTrials.gg
Burns
Why
  1. The study's listed conditions name Burns, a narrower term within Wounds and Injuries.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Metis Foundation · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Enrollment
77th of 272
48 · median 26
Started
2021
with 15 others
Phase 4
25 of 336
6 open now
Registered
262nd of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 77th largest by enrollment of the 272 interventional ones that give a count, is one of 16 that started in 2021, is one of 25 in phase 4, and was the 262nd registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of a novel Platform Wound Device (PWD) in its delivery of a local antibiotic, 0.1% Gentamycin cream, to prevent or treat infection in torso and extremity wounds. The hypothesis is that the PWD will be a safe and effective method to provide topical antibiotics to a torso or extremity wound, non-inferior to the current standard of care. This treatment will reduce or rapidly eradicate infection.

Read the detailed description

This is a prospective, randomized, controlled clinical trial comparing the use of a platform wound device as compared to standard of care to prevent or eliminate infection in torso and extremity wounds. Patients 18-85 years of age admitted for treatment of open wound(s) will be screened for inclusion criteria and asked to consent to participate in the randomized study. The first 10 patients will be treated with the PWD + gentamicin and will serve as a safety subset. Baseline measurement of serum antibiotic concentraion will be taken prior to PWD placement and one day after. Following the safety subset, 50 patients will be randomized to standard of care or to a single application of the PWD + gentamicin. Baseline assessments will be completed on day 0, including screening, pre-procedure wound evaluation, imaging, assessments, and specimen collection. Follow-up assessments will be completed and data gathered at days 1,2,3 and 4. All data collected of the study participants will be used to evaluate the PWD delivery of antibiotic.

03

Conditions studied

  • Wounds and Injury
  • Burn Wound
  • Infection Wound

Browse trials for

04

In context

Burns Reclassified

906 studies on the registry are indexed under Burns; 165 are open to participants now.

This study's enrollment of 48 is above the median of 40 across 664 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

The Metis Foundation is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Compared within Burns, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Wounds and Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater or equal to 18 and age less than or equal to 85
  2. Open wound up to 500cm2 in area with evidence of infection
  3. Exposure of deep dermis, subcutaneous tissue, muscle, fascia, tendon, or bone

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy
  2. Prisoner
  3. Active , use, or therapy
  4. Open fracture intimately involved with wound
  5. Underlying osteomyelitis
  6. Hardware or prosthetic exposure within wound
  7. Exposure of major named vessels or nerves
  8. Known allergy to gentamicin or other aminoglycosides
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Platform wound device with antibiotic

    Antibiotic cream will be applied to study wounds and then dressed with the platform wound device.

    Combination Product: Gentamycin with Platform Wound Device

  • No intervention
    Standard of Care

    Study wounds will be treated per the standard of care.

Interventions

  • Combination productGentamycin with Platform Wound Device

    Treatment of wounds with gentamycin and covered with platform wound device.

07

What researchers measure

Primary outcomes

  1. Feasibility of treatment

    Demonstration of the ability to enroll patients at a single institution to either the control group, receiving standard of care, or the treatment group, receiving PWD delivery and 1 dose of antibiotic (0.1% gentamicin cream) over 48 to 96 hours.

    Time frame: 48 to 96 hours

  2. Tolerability of treatment

    To demonstrate that patients are able to tolerate application of the PWD with 0.1% gentamicin cream application. Tolerability will be assessed by documentation of adverse events.

    Time frame: 48 to 96 hours

Secondary outcomes

  1. Effectiveness of wound swabs

    To demonstrate that wound swabs are an accurate and reliable measurement of infection based on semi-quantitative wound culture results.

    Time frame: 48 to 96 hours

08

Study locations

4 sites
  • Baptist Medical Center
    San Antonio, Texas 78205, United States
  • North East Baptist Hospital
    San Antonio, Texas 78217, United States
  • Mission Trail Baptist Hospital
    San Antonio, Texas 78235, United States
  • North Central Baptist Hospital
    San Antonio, Texas 78258, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Nov 2021, 9 months.

Of 21 phase 4 interventional studies under Burns, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 43. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 15, 2021
StartActual
Feb 8, 2021
Primary completionActual
Nov 19, 2021
CompletionActual
May 25, 2022
Last update
Oct 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04753723
Lead sponsor
The Metis Foundation
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Feb 8, 2021
Primary completion
Nov 19, 2021
Completion
May 25, 2022
Last update
Oct 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion